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Abstract: The delivery of large neutral amino acids
(LNAAs) to brain across the blood-brain barrier (BBB)
is mediated by the L-type neutral amino acid transporter
present in the membranes of the brain capillary endothe-
lial cell . In experimental animals, the L-system transporter
is saturated under normal conditions, and therefore an
elevation in the plasma concentration of one LNAA will
reduce brain uptake of others . In this study, we used
positron emission tomography (PET) to determine the
effect of elevated plasma phenylalanine concentrations
on the uptake of an artificial neutral amino acid, ["C]-
aminocyclohexanecarboxylate (["C]ACHC), in human
brain. PET scans were performed on six normal male
subjects after an overnight fast and again 60 min after
oral administration of 100 mg/kg of phenylalanine. The
plasma phenylalanine concentration increased by an av-
erage of 11-fold between the first and second scans. This
increase produced a reduction in ["C]ACHC uptake in
all brain regions but not in scalp. The mean ± SD influx
rate constant for whole brain decreased after phenylala-
nine ingestion from 0.036 ± 0.002 to 0.019 - 0.004 ml/g/
min. Kinetic analysis of the effect of plasma phenylalanine
concentration on the rate of ["C]ACHC uptake is com-
patible with a model of competitive inhibition so that large
increases in the concentration of one LNAA in plasma will
reduce the brain uptake of other LNAAs across the human
BBB. KeyWords: Aminocyclohexanecarboxylate-Posi-
tron emission tomography-L-system transporter-Es-
sential amino acids.
J. Neurochem. 64, 1252-1257 (1995) .
Because the blood-brain barrier (BBB) isolates the
brain from the blood, the delivery of many essential
metabolic substrates to brain is dependent on carrier-
mediated transport systems that are present in the
membranes of the brain capillary endothelial cell (Par-
dridge, 1983 ; Goldstein and Betz, 1986) . Large neutral
amino acids (LNAAs)belong to this group of essential
substrates because they cannot be produced by brain,
but they are required for the synthesis of proteins and
certain neurotransmitters . Indeed, it has been suggested
that the availability of amino acid precursors from the
blood may limit the synthesis of serotonin, histamine,
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phenylethylamine, tyramine, norepinephrine, kyn-
urenic acid, and quinofnic acid (reviewed elsewhere
by Pardridge, 1986 ; Smith, 1991 ) .
LNAAs enter brain via an L-type neutral amino acid
transporter that is present in the BBB (Pardridge, 1977,
1983 ; Smith et al ., 1987 ; Smith, 1991) . This trans-
porter has affinity for many naturally occurring amino
acids, which compete with each other for entry into
brain. Based on the results of kinetic analyses of
LNAA transport in animals, it has been proposed that
the L-system transporter of the BBB is nearly saturated
under normal conditions, and therefore an elevation in
the plasma concentration of one LNAA will reduce
brain uptake of others (Pardridge, 1986 ; Smith et al .,
1987 ; Smith, 1991) . Because phenylalanine has the
highest affinity for the transporter (Smith et al ., 1987 ;
Hargreaves and Pardridge, 1988), changes in its con-
centration have the greatest impact on the uptake of
other LNAAs. If this relationship is also true in hu-
mans, it may help to explain the brain dysfunction that
occurs in phenylketonuria (Kaufman, 1977 ; Pardridge,
1986) and the inconsistent response seen in some pa-
tients with Parkinson's disease who are treated with
L-DOPA (which is also transported by the L-system)
at various times after meals (Daniel et al ., 1976 ; Carter
et al ., 1989) . It is also compatible with the proposal
that the ingestion of large amounts of the low-cal-
orie sweetener aspartame (L-aspartyl-L-phenylalanine
methyl ester) might increase plasma phenylalanine
concentrations enough to affect brain amino acid me-
tabolism (Pardridge, 1986) . However, in a previous
study of LNAA transport into the human brain, we
found that a 2.5-fold increase in plasma phenylalanine
concentration resulting from the ingestion of an ex-
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censive amount of aspartame reduced the uptake of
a synthetic LNAA, [ "C ] aminocyclohexanecarboxylate
(I "CIACHC),by only 11 .5% (Koeppe et al ., 1991) .
Therefore, in the present study we determined the of
feet of a much larger change in plasma phenylalanine
concentration on LNAA transport into human brain by
administering phenylalanine itself rather than aspar-
tame .
MATERIALS AND METHODS
The preparation and use of ["C]ACHC for positron emis-
sion tomography (PET) studies have been described pre-
viously (Koeppe et al ., 1990). In brief, the radiotracer was
synthesized via a Bucherer-Strecker reaction of cyclohexa-
none with [ 'C]HCN in the presence of ammonium carbon-
ate and ammonium chloride according to the method of
Hayes et al . (1978) . The yield after purification by ion ex-
change chromatography was -100 mCi of ["C]ACHC.
This was diluted with normal saline and sterilized by filtra-
tion . The injection volume of 10 ml contained 30 mCi of
I''C]ACHC with an ACHC mass of <5 mg. Radiochemical
purity as judged by radio-HPLC was >98% . The absence
of unreacted cyanide was confirmed by colorimetric assay
before administration .
The research protocol was approved by institutional re-
view boards (Committee for the Use of Human Subjects in
Research and the Radioactive Drug Research Committee),
and informed consent was obtained from each subject before
their participation in the study. Six healthy male volunteers
21 -43 years old were recruited from the local community
by advertisement . Each underwent a brief history and physi-
cal and neurological examination and was judged to be in
good health and without neurologic abnormalities .
After an overnight fast, subjects reported to the PET labo-
ratory, and a catheter was placed in the radial artery . The
subjects' heads were aligned parallel to the canthomeatal
line and restrained by a band across the forehead attached
to a headholder . Each subject then received 30 mCi of [ "C] -
ACHC i.v . over 30 s. PET scanning was performed using a
Siemens model CTI 931/08-12 whole-body scanner. This
device generates 15 cross-sectional images (eight direct and
seven cross planes) and has an intrinsic resolution using the
nonwobbled mode of 5.8 mm full width at half-maximum
and a slice thickness of 6.5-8.0 mm. Baseline scans were
obtained as a dynamic sequence of 12 frames over a 60-min
period, i .e ., 5 X 1 min, 2 X 2.5 min, 2 X 5 min, 2 X 10
min, and 1 X 20 min, after which the subjects were removed
from the scanner and given 100 mg/kg of t_-phenylalanine
(General Nutrition Corp ., Pittsburgh, PA, U.S.A .) orally .
The dose of phenylalanine was divided so that 50 mg/kg
was given in capsules and 50 mg/kg was given as a slurry
in -300 ml of tap water. This combination was found to
give an optimal plasma phenylalanine curve. A pilot study
of two subjects indicated that the rise in plasma phenylala-
nine level was too protracted if only phenylalanine capsules
were used . At 60 min following administration of phenylala-
nine, the subjects received another 30 mCi dose of ["C]-
ACHC, and a second PET scan was acquired with the same
protocol .
During the PET scans, arterial blood was sampled for
determination of radioactivity and plasma amino acid con-
centrations . Samples for radioactivity were obtained as rap-
idly as possible during the first 2 min following [ 'C 1 ACHC
injection and then at progressively longer intervals, increas-
ing to 10 min by the end of the scan. Plasma was separated
by centrifugation and counted in a Nal scintillation well
counter. Blood samples for amino acid analysis were with-
drawn at -60 (immediately before the first scan), 0 (time
of phenylalanine ingestion), 10, 20, 30, 45, 60 (time of
second scan), 90, and 120 min, added to a small volume of
EDTA, and placed on ice . Blood cells were removed by
centrifugation, the plasma was deproteinized by centrifuga-
tion through an ultrafiltration membrane, and the filtrate was
removed and stored at -70°C. The plasma concentrations
of phenylalanine, tyrosine, methionine, leucine, isoleucine,
and valine were subsequently determined by HPLC (Hari-
haran et al ., 1993) .
A two-compartment, two-rate parameter tracer kinetic
model was applied to the dynamic PET data (Koeppe et al .,
1990) . This model provides estimates of the uptake rate
constant, K, (ml/g/min), describing the transport from
plasma across the BBB, and the clearance rate constant, k2
(1 /min), describing the rate of transport from brain back to
blood. The ratio of K, /k2 is a measure of the tracer distribu-
tion volume, DV (ml/g) . Functional images of the uptake
and clearance rate constants and DV were obtained from
a rapid pixel-by-pixel estimation procedure using weighted
integrals (Alpert et al ., 1984) . The first 3 min of data was
excluded from the analysis to minimize the effects of blood-
borne radioactivity (Koeppe et al ., 1990) . Mean K, and
k2 values were determined from seven predetermined brain
regions as well as from whole brain and scalp .
The rate of transport (u) of an amino acid in the presence
of multiple competing amino acids can be described by the
following equation, where C is the plasma concentration of
the amino acid, i is the plasma concentration of each compet-
ing amino acid, V,,x is the maximal rate of transport, Km is
a measure of the affinity of the amino acid, K,1 is its rate of
simple diffusion from blood to brain, and K; is the affinity
of each of the competing amino acids (Smith et al ., 1985) :
C + K, 1 + Y, ZK;}
When K, is independent of the rate of blood flow (Fenster-
macher et al ., 1981), v = K, - C and therefore
In this study, ACHC is used at a tracer concentration . There-
fore C = 0, and this equation can be rewritten as
acid such as phenylalanine (Phe) is given by
ACHCK
	












The effect of varying the concentration of a single amino
ACHC F'hc
KACHC = y i nax Ki + KACHC (4)
KACHC and the concentrations of phenylalanine and compet-
ing amino acids (i) are determined in our studies . Thus, if
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the K, values for the competing amino acids are known and
K;c"c is measured over a range of phenylalanine concentra-
tions, then we can estimate KPh`, KAc"c, and (Vm,x/K ,)AC"c
from Eq . 4 using standard nonlinear least-squares fitting pro-
cedures .
To increase the number of data points and to include
subjects with an intermediate rise in plasma phenylalanine,
we combined our previously reported results from subjects
receiving aspartame (Koeppe et al ., 1991) with those of the
present study . Because the previous study was performed
with a different PET scanner, the K, values obtained in that
study were normalized to the values obtained with the scan-
ner used in the present study by using the ratio of mean
baseline K, values for the new and old scanners (0.036/
0.031) .
Solution of Eq . 4 requires knowledge of the concentration
(i) and inhibition constants (K;) for the competing amino
acids . In most cases of competitive inhibition, the K; of an
inhibitor is the same as its affinity for the transporter, i .e .,
its K, n , as has been shown for the BBB LNAA transporter
(Pardridge, 1977) . As noted above, the concentrations of
tyrosine, methionine, leucine, isoleucine, and valine were
available, but neither K; nor K, values at the human BBB
in vivo are known . We therefore performed the analysis
using the values for K, reported in the rat (Smith et al .,
1987) and those reported for isolated human brain capillaries
(Hargreaves and Pardridge, 1988) .
Results for K,, k2 , DV, and levels of plasma amino acids
are reported as mean -- SD values . Statistical comparisons
of values obtained before and after phenylalanine ingestion
were made using a two-tailed Student's t test for paired
samples .
RESULTS
Fasting phenylalanine levels were 46 -- 8 pM, and
levels rose to 538 ± 240 AM at 30 min following
ingestion of 100 mg/kg of phenylalanine (Fig . IA) .
The mean values were stable through 90 min and then
declined. The concentration of tyrosine also rose after
phenylalanine administration (Fig . 1B), reflecting the
peripheral conversion of phenylalanine to tyrosine . At
the time of the second PET scan, tyrosine content was
increased approximately twofold (p < 0.01) . The con-
centrations of the other LNAAs quantified were not
significantly different at the time of the second scan .
Functional images of K, and DV for a typical subject
before and after phenylalanine administration are
shown in Fig . 2, and mean ± SD values for selected
brain regions, whole brain, and scalp are shown in
Table 1 . Whole-brain values (mean + SD) for K, de-
creased from 0.036 ± 0.002 to 0.019 ± 0.004 ml/g/
min (p < 0.0001) after phenylalanine ingestion . All
brain regions examined showed a similar reduction ;
however, K, in the scalp was not significantly changed .
In contrast, changes in k 2 , the rate constant for ["C]-
ACHC efflux from brain, were smaller. This might
indicate that, over the interval of this study, the concen-
tration of phenylalanine in the brain's interstitial fluid
did not increase as substantially as it did in the blood .
The relationship between whole-brain K, and plasma
phenylalanine concentrations for the six subjects of
J. Neurochem., Vol . 64, No . 3, 1995
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FIG . 1 . Change in plasma LNAA concentrations after oral admin-
istration of 100 mg/kg of phenylalanine . Blood samples were
obtained 1 h before (-60 min) and at various times after inges-
tion of phenylalanine at zero-time . Data for phenylalanine (A)
and other LNAAs (B) are mean -- SD (bars) values of determina-
tions from six subjects .
this study and another eight subjects that were given
aspartame in a previous study is shown in Fig . 3 . The
concentration-dependent reduction in K, is consistent
with competitive inhibition of [ "C ] ACHC uptake by
phenylalanine. To determine the kinetic constants for
transport, we fitted these data to Eq . 4 using the Km
values for amino acids other than phenylalanine that
have been reported in rats (Smith et al ., 1987) and in
microvessels isolated from human brain (Hargreaves
and Pardridge, 1988) . In general, the Km values are
eight- to 40-fold lower in the latter compared with the
former study . As shown in Table 2, both analyses give
similar values for the rate of ACHC diffusion into
brain, values that are slightly greater than the 0 .0060-
0.0096 ml/g/min reported for ACHC diffusion into
rat brain (Aoyagi et al ., 1988) . In addition, the K;
values calculated for phenylalanine are similar to the
experimentally determined values of 11 AM in the rat
(Momma et al ., 1987 ; Smith et al ., 1987) and 0.3 AM
in isolated human brain microvessels (Hargreaves and
Pardridge, 1988) .
FIG. 2. Representative ["C]ACHC PET scans for one
subject before and 60 min after oral administration of
phenylalanine. Images at four different levels show the
marked reduction in the influx rate constant (K I ) for
ACHC in most brain regions but not in the scalp.
DISCUSSION
The kinetics of LNAA amino acid transport across
the BBB of various animals have been extensively
studied . Smith et al . ( 1987) used an in situ rat brain
perfusion technique to measure the unidirectional
fluxes from the blood to the brain of' labeled amino
acids while eliminating or controlling the concentra-
tion of all other competing amino acids in the perfu-
sate . The affinity of various LNAAs for the transporter
varied from I 1 pM for phenylalanine to >200 IlM for
valine . Using this same technique, the K , of ACHC
for the rat BBB transporter was determined to be 54
pM (Aoyagi et al ., 1988), near that of methionine,
isoleucine, and valine (Smith et al ., 1987) . For most
LNAAs, the measured affinities are similar to or less
than their usual plasma concentrations, and therefore
one can predict that the transporter operates near its
maximal rate under normal conditions . As a result,
when the plasma concentration of one amino acid in-
creases, the brain uptake of other amino acids decrease .
This effect is greatest with increased plasma concentra-
'TABLE I . Regional BBB transport cale constants and tissue DV values . tbr ACHC hre- and husladntinistralion
of 100 niglkg 4/ hhenvlalaninee
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Data are mean ± SD values obtained from six subjects .
"p < 0.05, "t) < 0.0001, p < 0.005 compared with the corresponding baseline value.
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tions for those amino acids that have the highest affin-
ity for the transporter, such as phenylalanine .
It is not surprising that there are few prior studies
of LNAA transport across the BBB of humans and that
there are no kinetic studies of competitive inhibition
in vivo . An early study by Oldendorf et al . ( 1971 )
indicated that the brain uptake of [ "Se l seleno-
methionine is reduced in phenylketonurics . Leenders
et a] . ( 1986) demonstrated reduced brain uptake of 6-
J'"Fjfluoro-i,-DOPA measured by PET in a patient
who received an intravenous infusion of eight LNAAs .
Bergström et al . ( 1987) used PET to demonstrate that
the accumulation rate of L-[ "C I methionine was de-
creased by -35% in normal brain after intravenous
infusion of an amino acid mixture containing leucine,
isoleucine, and valine . Using both a dual-probe posi-
tron detection system and PET, O'Tuama et al . ( 1988)
measured
	
the influx rate constant for L- I "C (-
methionine in normal subjects before and after the oral
consumption of 100 mg/kg of phenylalanine. Influx
decreased by an average of 33% following oral phenyl-












scalp 0.032 ± 0.004 0.028 ± 0.006 0.054 ± 0.004 0.053 ± 0.011 0.60 - 0.06 0.55 - 0.06"
Whole. brain 0.036 - 0.002 0.019 0.004' 0.041 ± 0.004 0.034 ± 0.004' 0.88 0.06 0.55 ~- 0.09
FFrontal cortex 0.040 ± 0.003 0.019-~ 0.004" 0.043 + 0.004 0.035 1 - 0.006" 0.92 ± 0.07 0.56 - 0.12'
Parietal cortex 0.035 + 0.002 0.016 0.004" 0.044 0.003 0.032 ± 0.007' 0.81 - 0.05 0.49 ± 0.07'
Temporal cortex 0.038 ± 0.003 0.019 ± 0.004" 0.042 ± 0.003 0.036 ± 0.008 0.91 ± 0.07 0.54 + 0.12'
Thalamus 0.045 ± 0.003 0.022 ± 0.005" 0.048 ± 0.003 0.039 ± 0.009" 0.94 - 0.10 0.56 , 0.1 1'
Caudate nucleus 0.036 ± 0.005 0.017 ± 0.002' 0.036 ± 0.003 0.029 ± 0.005" 1 .00 ± 0.10 0.61 -~ 0.12'
Putamen 0.043 ± 0.003 0.019 ± 0.004" 0.042 ± 0.005 0.032 - 0.007" 1 .02 + 0.05 0.62 ± 0 .13'
Cerebellar cortex 0.047 ± 0.003 0.021 ± 0.004" 0.052 1 0.005 0.037 ~- 0.008' 0.91 + 0.12 0.58 0.12
/256
FIG. 3. Relationship between ["CIACHC influx rate constant
and plasma phenylalanine concentration . Data were obtained
from the six subjects reported in the present study before (e) and
after (") oral ingestion of phenylalanine and from a previously
reported study (Koeppe et al ., 1991) of eight subjects before
((%) and after (C .i) oral administration of aspartame. Plasma phe-
nylalanine concentrations were determined at the end of the
baseline scan just before ingestion of phenylalanine or aspar-
tame (zero-time) and 60 min after ingestion of phenylalanine or
aspartame at the time the second scan was started.
alanine in four subjects analyzed by the dual-probe
system, but it decreased in only two of three patients
evaluated by PET. The brain uptake rate calculated
from the data obtained in normal subjects using the
dual-probe system (1 .4 nmol/g/min) is similar to the
rate of methionine transport across the BBB of the rat
measured in the presence of normal plasma concentra-
tions of other amino acids (1 .7 nmol/g/min) (Smith
et al . . 1987) .
Knudsen et al . (1990) used a double indicator tech-
nique to measure the uptake and efflux of radiolabeled
phenylalanine, tryptophan, leucine, tyrosine, and argi-
nine under basal conditions . They concluded that there
was marked asymmetry of transport, with amino acid
transport from brain to blood occurring at a rate that
was eight to 12 times greater than from blood to brain .
Subsequently, they showed that the efflux rate constant
but not the influx rate constant for phenylalanine was
reduced in patients with hepatic encephalopathy
(Knudsen et al ., 1993) . In contrast, we did not observe
very large differences in the influx and efflux rate con-
stants for ACHC transport under baseline conditions
(Table I ) . This apparent discrepancy may be ex-
plained by the proposed asymmetry of BBB amino
acid transporters . For example, one model has the A-
system amino acid carrier on only the abluminal mem-
brane and the L-system carrier on both the luminal
and abluminal membranes (Betz and Goldstein, 1978,
1986) . The amino acids studied by Knudsen et al .
(1990) have affinity for both carriers, whereas ACHC
has affinity for only the L-system (Matthews and Zand,
1977) .
The kinetics of phenylalanine transport into mi-
J. Neur-nrhem_ Vol . 04, Nu . i, 1995
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crovessels isolated from human brain were studied by
Choi and Pardridge ( 1986) . The results of competitive
inhibition studies using this in vitro preparation sug-
gested the presence of two phenylalanine transport sys-
tems : one with a K , of 22 p,M, a value similar to that
observed in the rat in vivo, and a second, very-high-
affinity transport system (K , = 0.26 pM) . However,
in a later study, Hargreaves and Pardridge (1988) mea-
sured the transport of eight LNAAs into isolated brain
microvessels and concluded that the high-affinity
transport system was more important . K , values varied
between 0.30 pM for phenylalanine and 8 .8 pM for
valine .
It is probably not possible to relate directly the re-
sults of in vitro studies using isolated cerebral capillar-
ies with those of in vivo studies . In isolated capillaries,
it is uptake across the abluminal rather than the luminal
membrane that predominates, whereas transport across
the luminal membrane is measured in vivo . Only the
lower-affinity transporters are seen in the in vivo ex-
periments (Smith et al ., 1987) . Differences in the ki-
netic constants measured with in vitro as compared
with in vivo techniques may be related to the pre-
viously mentioned asymmetry of BBB amino acid
transporters (Betz and Goldstein, 1978 ; Goldstein and
Betz, 1986 ; Smith, 1991) . Thus, it is unlikely that the
differences between the in vivo rat experiments and
the in vitro experiments with human microvessels are
due to a species difference .
The results obtained in vivo are consistent with the
presence of the lower-affinity transporter of the two
that have been described in isolated brain capillaries,
but the affinity of this transporter is believed to be
quite high in comparison with the LNAA transporter
in other tissues (Pardridge, 1986; Smith, 1991) . Our
studies support this idea, because the scalp did not
exhibit the same competitive inhibition of ACHC up-
take as did the brain .
In summary, the value for K ip" that was calculated
in the present study supports the proposal that there is
a substantial degree of saturation of the LNAA trans-
porter at the human BBB . Thus, in the presence of
TABLE 2 . Kinetic parameters fir inhibition of ACHC
transport by phenylalanine
Variability of all values is <I 0% as judged by analysis of the
covariance matrices .
Smith et al . (1987) .
" Hargreaves and Pardridge (1988) .





K','"` (pM) 13 .2 1 .00
V /K,,, for ACHC (ml/g/
min) 0.302 3.73
K ',"u` (ml/g/thin) 0.0119 0.0129
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rather large and persistent increases in plasma amino
acid concentrations, as occurs in certain human meta-
bolic diseases, LNAA uptake by brain might indeed
be reduced sufficiently to compromise the synthesis of
proteins and neurotransmitters .
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